Varicella-Zoster virus (VZV) causes chickenpox and shingles. Although infection is 15 associated with severe morbidity in some individuals, the molecular mechanisms that 16 determine innate immune responses remain poorly defined. We found that the 17 cGAS/STING DNA sensing pathway was critically required for type I interferon (IFN) 18
INTRODUCTION 29 30
Varicella-Zoster virus (VZV) is one of nine herpes viruses that infect humans (Arvin and 31 Gilden, 2013). VZV is an alpha-herpesvirus, closely related to Herpes Simplex virus 32 (HSV) 1 and 2. It has a 125kb dsDNA genome, the smallest of the human 33
herpesviruses. The genome includes at least 70 open reading frames (ORFs). Primary 34 infection causes chickenpox (Varicella) . Like all human herpes viruses, VZV 35 establishes life-long latency in an infected host and can reactivate as shingles (Zoster). 36
Shingles is a debilitating disease with significant associated morbidity. During both 37 primary infection and reactivation, the virus can gain access to the central nervous 38
system and cause severe complications such as encephalitis and vasculitis (Nagel and 39 Gilden, 2014). Despite introduction of the live-attenuated chickenpox vaccine in the 40 early 1990s, the virus remains highly prevalent worldwide (WHO, 2014). 41
The type I IFN system lies at the forefront of host defence against infectious pathogens 42
and is indispensable for successful control of viral infections (McNab et al., 2015) . The 43 expression of these cytokines is induced following pattern recognition receptor (PRR) 44
activation. PRRs are a heterogenous group of proteins that can respond to a diverse 45 array of pathogen-associated molecular patterns (PAMPs) (Brubaker et al., 2015) . The 46
recognition of viral pathogens relies to a large extent on sensing of nucleic acids ( and other type I and type III IFNs, as well as inflammatory cytokines. Other proteins, 57 such as IFI16, RNA polymerase III, and DNA-PK have been described to be accessory 58 proteins to the cGAS/STING system or constitute independent DNA-sensing 59 mechanisms (Dempsey and Bowie, 2015) . 60 Type I IFNs are secreted cytokines that act in an autocrine, paracrine, or systemic 61 manner by binding to the type I IFN receptor (IFNAR) (McNab et al., 2015) . Canonical 62 IFNAR signalling results in the phosphorylation and heterodimerisation of the 63 transcription factors STAT1 and STAT2. After recruitment of IRF9, this protein complex 64 drives expression of hundreds of genes, termed interferon-stimulated genes (ISGs). 65
Among others, ISGs contain genes that encode PRRs, proteins involved in type I IFN 66
induction and signalling, negative and positive feedback regulators, restriction factors 67 acting directly on viruses, and proteins that are involved in adaptive immune responses 68 (Schoggins, 2019; Schoggins et al., 2011) . 69 Despite the fact that VZV is a highly prevalent and important human pathogen, its 70 pathogenesis is still poorly understood. The lack of suitable small animal models that 71 recapitulate primary infection and latency establishment has hampered the molecular 72 characterisation of its life cycle in vivo (Haberthur and Messaoudi, 2013) . During its 73 dissemination in the human host, the virus infects a multitude of different cells. Infection 74 of T cells, keratinocytes, neurons, and epithelial cells is indispensable for VZV's life 75
cycle (Zerboni et al., 2014) . In addition, immune cells including dendritic cells (DCs), 76 monocytes, and NK cells are capable of supporting VZV replication in vitro and are 77 potentially relevant for in vivo spread (Abendroth et al., 2001; Campbell et al., 2018; 78 Kennedy et al., 2019; Morrow et al., 2003; Wang et al., 2005) . However, the events that 79 govern the cell-intrinsic recognition of the virus in these cell types and the antiviral 80
cytokine response have only begun to be elucidated in vitro. The DNA sensor TLR9 is 81 partly responsible for IFNα secretion after infection of plasmacytoid DCs (Yu et al., 82 2011) . In dermal fibroblasts, STING is required for type I and type III IFN production 83 (Kim et al., 2017 ). An interesting genetic link between DNA sensing via RNA polymerase 84 III and VZV CNS infection has been uncovered recently (Carter-Timofte et al., 2018). 85
Although a comprehensive characterisation of the role of these DNA sensing pathways 86 during VZV infection is lacking, current evidence suggests that type I IFNs are of critical 87 relevance for control of VZV infection. Increased IFNα levels can be detected in the 88 serum of patients with primary VZV infection (Arvin et al., 1986) . In addition, the potency 89 of type I IFNs in restriction of VZV replication has been demonstrated in vitro ( Mainka et al., 1998) . In addition to wild-type (WT) THP1 cells, we 114 tested previously described KO lines lacking cGAS, STING, TBK1, MyD88, or IFNAR2.
115
We further generated MAVS KO and IRF3 KO cells using CRISPR/Cas9 technology 116 (see Materials and Methods and Figure S1 ). All THP1 KO cells were validated by 117
immunoblotting for the absence of protein and functionally by stimulation with DNA, 118
RNA and type I IFN ( Figure S2 ).
119
Upon treatment with PMA, THP1 cells adopt a macrophage-like, adherent and highly 120 responsive phenotype. Given the difficulties of working with cell-free VZV (Caunt and  121 Taylor-Robinson, 2009; Chen et al., 2004), we used co-culture with VZV-infected (+VZV) 122
MeWo cells to infect PMA-treated THP1 cells; co-culture with uninfected MeWo cells 123 served as a control ( Figure S3A ). MeWo cells are a melanoma cell line that is well-124 established for VZV propagation. After 48 hours of co-culture, cells were harvested for 125
RT-qPCR, immunoblotting, and flow cytometry analysis. Before co-culturing, THP1 126 cells were labelled with a fluorescent tracer dye to distinguish inoculum (MeWo) and 127 target (THP1) cells during flow cytometry analysis ( Figure S3A,B ). For all experiments, 128
uninfected MeWo cells were additionally used as target cells. MeWo cells do not 129 induce type I IFNs in response to VZV ( Figure 1 ). Infected cells within the target cell 130 population were identified by cell-surface staining for the VZV glycoprotein E 131 (gE)/glycoprotein I (gI) complex ( Figure S3B ) (Mo et al., 2003) . 132
Due to the nature of the co-culture, cells harvested for RT-qPCR and immunoblotting 133 contained both target and inoculum cells. Flow cytometry analysis revealed that across 134 genotypes, target cells constituted between 50% and 85% of all cells in uninfected 135 samples and between 70% and 95% in infected samples ( Figure S3C ). Amongst target 136 cells, the infected cell population constituted between 10% and 30% of cells ( Figure  137 S3D). This showed that all THP1 KO cell lines tested here were permissive for VZV 138
infection.
140
The Type I IFN Response to VZV Requires the DNA Sensor cGAS 141
To investigate whether THP1 cells induce type I IFNs in response to VZV we analysed 142 mRNA expression levels of IFNB1 (encodes IFNβ) and IFI44, an ISG. In WT THP1 143 cells, both transcripts were robustly induced after VZV infection ( Figure 1A ). Similar 144 results were obtained using MyD88 KO and MAVS KO cells. In contrast, no 145 transcriptional upregulation of IFNB1 or IFI44 was observed in THP1 cells lacking 146 cGAS, STING, TBK1, IRF3, or IFNAR2. 147
Immunoblot analysis showed that the transcription factors STAT1 and STAT2 were 148 only phosphorylated in WT, MyD88 KO, and MAVS KO cells ( Figure 1B) . In contrast, 149 no p-STAT1 and p-STAT2 signals were observed in cells lacking cGAS, STING, TBK1, 150
IRF3, or IFNAR2. This indicated that only WT, MyD88 KO and MAVS KO cells secreted 151 type I IFNs in response to VZV infection. Consistently, STAT1 and RIG-I, which are 152 both encoded by ISGs, were upregulated at protein level only in the cells showing 153 STAT1/2 activation ( Figure 1B ). Importantly, we could not observe phosphorylation of 154 STAT1/2 or increased abundance of STAT1 and RIG-I in infected MeWo cells. 155
Western blotting with antibodies against VZV-gE/gI and VZV ORF62 confirmed that all 156 cell lines became infected. 157
Determination of CXCL10 (IP-10) levels in co-culture supernatants confirmed the 158 findings of our RT-qPCR and immunoblot analyses. WT, MyD88 KO, and MAVS KO 159 THP1 cells produced low levels of CXCL10 at baseline and these were increased after 160 infection with VZV ( Figure 1C proteins by immunoblot using an antibody against the V5-tag ( Figure S4 ). 59 of 72 185 constructs (82%) were expressed and bands at the expected molecular weights were 186 detected. Five constructs were expressed but at the wrong size, and eight were not 187 expressed at all. This VZV ORF library is a resource for the scientific community and 188 is available to all interested scientists. 189 and standard deviation of all data points was then used to calculate Z-values, which 202
represent the number of standard deviations an individual data point is diverging from 203 the mean. We used these Z-scores to rank ORFs in their ability to block IFN activation 204 downstream of cGAS/STING ( Figure 2A ). KSHV ORF52, a previously described 205 cGAS-antagonist (Wu et al., 2015) , and the L protein of EMCV, a previously described 206
IRF3-antagonist (Freundt et al., 2018) , served as positive controls. As expected, we 207
found these with the lowest ranks (i.e. smallest fold change) in our assay and both 208 potently blocked firefly luciferase induction. In addition, we identified a number of VZV 209
ORFs that showed similar behaviour. The two aforementioned IRF3 antagonists 210 expressed by VZV, ORF61 and ORF62, were among them, which further validated our 211 approach.
212
We performed this screening experiment three times; Figure 2B displays the results as 213 a heatmap. We identified a number of ORFs that reproducibly ranked very low. To 214 identify VZV proteins that specifically block the cGAS and/or STING, and not 215
downstream signalling proteins such as IRF3 that are also activated by other PRRs, 216
we compared selected hits from the primary screen in their ability to block reporter 217 activation by overexpression of cGAS/STING or RIG-I-CARD (data not shown). RIG-I-218
CARD is a constitutively active variant of RIG-I that activates the IFNB1 promotor via 219 MAVS. A direct cGAS/STING antagonist is therefore unable to block this stimulation. 220
We identified the protein encoded by ORF9 of VZV to selectively block reporter 221 activation by cGAS/STING but not RIG-I-CARD when compared to empty vector 222 ( Figure 2C ).
223
We then aimed to verify that VZV ORF9 has the ability to antagonise activation of 224 cGAS by dsDNA in an endogenous setting. THP1 monocytes were stably transduced 225
with expression constructs for ORF9-V5 or for GFP-V5 as a negative control ( Figure  226 2D). We stimulated cGAS in these cells by transfection of increasing doses of dsDNA 227
and measured expression levels of IFNB1 mRNA and IFNL1 mRNA (encoding a type 228 III IFN) by RT-qPCR ( Figure 2E ). As expected, THP1 cells expressing GFP showed a 229
dose-dependent increase in expression of both transcripts. In contrast, cells 230 expressing ORF9 did not respond to low doses of DNA. At higher doses, their response 231 was attenuated when compared to GFP-expressing cells. Collectively, these data 232
revealed that the VZV ORF9 protein prevented cGAS/STING activation. 233 234
VZV ORF9 Interacts With cGAS 235
We hypothesised that VZV ORF9 exerts its antagonistic function by directly interacting 236
with either cGAS or STING. To test this, HEK293T cells were transiently transfected 237 with expression constructs for cGAS-FLAG, STING-HA, and ORF9-V5 and protein 238 interaction was analysed by immunoprecipitation (IP). We used antibodies against the 239 epitope tags and analysed IP fractions by immunoblotting ( Figure 3A ). All ectopically 240 expressed proteins were precipitated efficiently, and an IgG isotype control antibody 241 did not precipitate any of the proteins tested. Interestingly, ORF9 was detected in the 242 bound fraction after cGAS IP. The reverse IP confirmed this result: we found cGAS in 243 the ORF9 IP. In contrast, ORF9 did not interact with STING in this assay ( Figure 3A ). 244
To verify that this interaction occurred with endogenous cGAS, we used THP1 cells 245
stably transduced to express FLAG-ORF9, which was precipitated from cell lysates 246
with α-FLAG antibody. Indeed, endogenous cGAS was present in the IP fraction; IP of 247 FLAG-GFP served as a negative control ( Figure 3B ). 248
Next, we asked whether ORF9 expressed from its endogenous promotor during viral 249 infection had the ability to interact with cGAS. We used a recombinant VZV that 250 expressed C-terminally V5-tagged ORF9 from its endogenous genomic locus. We 251 infected THP1 cells and HaCaT cells (a keratinocyte cell line that expresses cGAS) 252
with WT VZV or VZV ORF9-V5 and performed α-V5 IP ( Figure 3C ). In both THP1 and 253
HaCaT cells infected with VZV ORF9-V5 , endogenous cGAS co-precipitated with ORF9. 254
These data showed that endogenous ORF9 protein expressed by the virus in infected 255 cells interacted with cGAS. 256
To investigate whether the two proteins interact in living cells, we overexpressed 257 tagged ORF9 and cGAS in HEK293T cells and performed immunofluorescence 258 analysis ( Figure 3D ). Expression of ORF9 alone resulted in cytoplasmic staining. 259
Similarly, cGAS was detected in the cytoplasm. We further observed cGAS foci co- In order to biochemically characterise the interaction between ORF9 and cGAS in more 267 detail, we performed experiments in a cell-free system. We expressed cGAS, cGAS-268
HA, FLAG-ORF9, and FLAG-GFP in E. coli and performed single-step purification 269
( Figure S5 ). First, we tested whether ORF9 and cGAS interacted directly using the far 270 western protocol ( Figure 3E ). FLAG-ORF9 or FLAG-GFP protein were separated on a 271
denaturing SDS-PAGE gel and transferred to a membrane. The proteins on the 272 membrane were then re-natured and incubated with recombinant cGAS as a probe.
273
Possible binding of cGAS to proteins on the membrane was then tested using α-cGAS 274
antibody. Indeed, we found that probing for cGAS resulted in a signal at the size of 275 ORF9 ( Figure 3F ). Importantly, cGAS did not bind to GFP.
276
We then tested interaction of the two recombinant proteins using immunoprecipitation.
277
FLAG-ORF9 or FLAG-GFP were incubated with cGAS-HA in the test tube. The 278 proteins were then precipitated using antibodies against the epitope tags. Immunoblot 279 analysis of the IP fractions showed that cGAS was co-immunoprecipitated with ORF9 280
but not GFP ( Figure 3G ). The reverse IP of cGAS resulted in binding of both ORF9 281 and GFP; however, the signal was stronger for ORF9. These data established that 282 VZV ORF9 and cGAS interacted without the requirement for another cellular or viral 283
protein.
284
To gain insight into possible structural features of ORF9 we used the PSIPRED 4.0 285 algorithm to predict its secondary structure based on the amino acid sequence (Buchan 286 and Jones, 2019). This analysis predicted a four sheet -helix motif in the N-terminal 287 region and a two helix -sheet -helix motif in the C-terminal region of ORF9 ( Figure  288 4A). Using six ORF9 truncation mutants ( Figure 4A ), we tested whether these putative 289 structural elements were involved in the interaction with cGAS. Firstly, we 290 overexpressed both human cGAS and ORF9 mutants in HEK293T cells. Consistent 291 with our earlier observation, full-length ORF9 co-immunoprecipitated cGAS. The C-292
terminal half of ORF9 (construct II) behaved the same, while the N-terminal half 293
(construct I) failed to interact with cGAS. ORF9 constructs III, IV, and V also pulled 294 down cGAS. All ORF9 constructs that interacted with cGAS shared amino acids (AA) 295 151 to 240. Interestingly, this region harbours the predicted two helix -sheet -helix 296 motif. However, IP of ORF9 151-240 (construct VI) did not co-precipitate cGAS ( Figure  297 4B). Secondly, we tested whether endogenous cGAS interacted with selected ORF9 298 truncation mutants stably expressed in THP1 cells. Consistent with the data from 299
HEK293T cells, we found that full-length ORF9 and constructs II and V interacted with 300 endogenous cGAS, while constructs I and VI did not ( Figure 4C ). Taken together, 301 these biochemical and imaging data established that VZV ORF9 and cGAS were 302 interaction partners. Furthermore, our results suggested that the central portion of 303 ORF9 (construct VI, AA 151-240) was required but not sufficient for this interaction. 304
However, it is also possible that ORF9 The DNA was then precipitated using streptavidin beads and the presence of bound 313 proteins was analysed by immunoblotting ( Figure 4D ). In the absence of DNA, none of 314 the proteins were precipitated. As expected, cGAS bound to DNA. Interestingly, ORF9 315 also was pulled down by DNA, both alone and in the presence of cGAS. GFP did not 316
bind DNA under any conditions. These data show that ORF9 bound DNA, which may 317 be related to its activity as a cGAS antagonist. 318 319 VZV ORF9 Prevents cGAMP Synthesis 320 cGAS activation by dsDNA results in the synthesis of cGAMP. Given our findings that 321
ORF9 blocked DNA sensing and interacted with cGAS and DNA, we next tested 322 whether ORF9 prevents cGAMP production. Transfection of HEK293T cells with 323 plasmids encoding GFP-tagged HIV-1 gag and VSV-G results in the production of 324 VSV-G pseudotyped, HIV-1 GFP-capsid containing virus-like particles (VLPs). Co-325 expression of cGAS during VLP production leads to the presence of cGAMP within the 326 particles (Bridgeman et al., 2015; Chauveau et al., 2020) . We hypothesised that the 327 presence of ORF9 during VLP production blocks cGAS activation and thus prevents 328 the presence of cGAMP in VLPs. We produced VLPs in the presence or absence of 329 cGAS with additional co-transfection of ORF9, or GFP as a negative control ( Figure  330 5A). VLP producer cells were analysed by immunoblotting ( Figure 5B ). Infection of 331
HEK293 cells and quantification of GFP-positive cells by flow cytometry confirmed 332 equivalent infectivity of the different VLP preparations ( Figure 5C , S6 Anemone species that have diverged from humans more than 500 million years ago 421 harbour cGAS-like enzymes (Kranzusch et al., 2015) . This indicates that a common 422
ancestral organism expressed such proteins. It further opens up the possibility that 423 ancient herpes viruses evolved the relevant evasion strategies. We hypothesise that 424 antagonism of cGAS by herpesviruses constitutes an ancient molecular mechanism 425 that evolved long before the advent of antiviral cytokines and IRF3 during evolution. 
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462
(A) THP1 cells of the indicated genotypes were mock infected or infected with VZV by co-culture as described in 463 Figure S3 . The mRNA expression levels of IFNB1 (encoding IFNβ) and IFI44 were analysed by RT-qPCR.
464
Expression levels were normalised to GAPDH and are shown as fold changes relative to levels in uninfected cells. 
MATERIALS AND METHODS
548
Cells 549 550
All cells were cultured at 37°C and 5% CO2 and checked regularly for mycoplasma 551 contamination. Adherent cells were passaged using Trypsin-EDTA (0.25%) 552 dissociation reagent (Gibco) at appropriate confluence. FCS was obtained from Sigma-553
Aldrich. HEK293 and HEK293T cells (gifts from Caetano Reis e Sousa, The Francis 554
Crick Institute, UK) were maintained in DMEM (Sigma-Aldrich) containing 4.5 g/L 555 glucose, supplemented with 10% (v/v) FCS and 2mM L-glutamine (Gibco) (DMEM 556 complete). HEK293-ISRE-Firefly luciferase reporter cells (clone 3C11) were described 557
previously (Bridgeman et al., 2015) . CARD was a gift from Andreas Pichlmair (Technical University Munich, Germany). 586
pCMV-VSV-G was a gift from Bob Weinberg (Addgene number 8454). The lentiviral 587 packaging plasmid p8.91 was a gift from Greg Towers (University College London). 588
pGag-eGFP was from the NIH AIDS reagent programme (number 11468). 589 pX458/Ruby/MAVS was described previously (Hertzog et al., 2018) . pCMV-3tag-KSHV-590 ORF52 was a kind gift from Fanxiu Zhu (Florida State University, USA). 591 pX458/Ruby/IRF3 was created as described for the MAVS-targeting plasmid. A sgRNA 592
targeting exon 3 of the IRF3 locus was designed using the MIT algorithm 593 (crispr.mit.edu) and cloned into the px458 vector. The pLenti6.3/EMCV-L-V5 plasmid 594 was described previously (Hertzog et al., 2018) . 595 596
Cloning 597 598
Mammalian expression plasmids for hcGAS and hSTING were created by PCR-599 amplification using THP1 cDNA and ligation into the gateway entry vector pCR8. 600
Coding sequences were shuttled into expression vectors (pLenti6.3/C-V5, 601
pcDNA3.2/C-FLAG, pcDNA3.2/C-HA) via Gateway recombination. Mammalian 602 expression plasmids for eGFP (pLenti6.3/puro/N-FLAG, pDEST31/N-FLAG) were 603 created in a similar way by PCR amplification from pGag-eGFP introducing a stop 604 codon. VZV ORF9 expression plasmids (pLenti6.3/puro/N-FLAG, pDEST31/N-FLAG) 605
were created by amplification of ORF9 with a stop codon and gateway recombination. 606
Expression plasmids for ORF9 truncation mutants (pLenti6.3/puro/N-FLAG) were 607 created by PCR amplification of the respective coding sequence with a start and stop 608
codon. Bacterial expression vectors for FLAG-ORF9, FLAG-GFP, and hcGAS-HA 609
were created by PCR-amplification of the coding sequences from existing plasmids 610 and restriction enzyme cloning into pGEX6P1. pGEX6P1 and pGEX6P1-hcGAS were 611 a kind gift from Martin Reijns (University of Edinburgh, UK). All primer sequences are 612 listed in Table S1 . 613 614
VACV 70mer-Biotin dsDNA 615 616
A 70bp immunostimulatory dsDNA fragment from VACV was described previously 617 (Unterholzner et al., 2010) . Two complementary oligos were synthesised (Sigma Aldrich) 618
and combined at equal molar ratio. The solution was heated to 95°C and allowed to 619 anneal by cooling to RT. 620
Forward sequence: 621 5'-ccatcagaaagaggtttaatatttttgtgagaccatcgaagagagaaagagataaaacttttttacgact-3'-622 TEG-Biotin 623
Reverse sequence: 624 5'-agtcgtaaaaaagttttatctctttctctcttcgatggtctcacaaaaa-tattaaacctctttctgatgg-3' 625 626
Antibodies 627 628
For immunoblot: beta-actin-HRP (AC-15, Sigma Aldrich), FLAG-HRP (clone M2, 629
Sigma Aldrich), V5-HRP (R961-25, Invitrogen), RIG-I (Alme1, Calteg Medsystems), 630
VZV HEK293T cells were seeded at 3.5x10 4 cells per well in 96-well plates. On the following 683 day, cells were transfected with the following plasmids using Lipofectamine 2000 684 (Invitrogen): 20ng p125-F-Luc, 5ng pRL-TK, 1ng hcGAS, 25ng hSTING, and 50ng of 685 a VZV ORF. Alternatively, cells were transfected with 5ng RIG-I-CARD plasmid instead 686 of cGAS and STING plasmids. The next day, expression of firefly and renilla 687 luciferases was assessed using Dual Luciferase assay system (Promega). 688 689
Lentivirus Production and Transduction 690 691
1.2x10 7 HEK293T cells were seeded in 15cm cell culture dishes. The next day, cells 692
were transfected with 9µg lentiviral expression plasmids harbouring the gene of 693
interest, 9µg p8.91 plasmid, and 3µg pVSV-G using Lipofectamine 2000. 16 hours 694
later, medium was replaced with fresh growth medium. 24 hours later, lentivirus 695
containing supernatant was harvested, clarified by centrifugation, and stored at 4°C. 696
Cells were overlaid with fresh growth medium. 8 hours later, supernatants were 697
harvested again and pooled with previous supernatants. After 16 hours, lentivirus 698 containing supernatants were harvested for a third time. Pooled supernatants from all 699 three harvests were filtered through a 0.45µm filter, aliquoted into cryovials and stored 700 at -80°C. For transduction of cells, polybrene (Sigma Aldrich) was added to lentiviral 701 supernatants to a final concentration of 8µg/ml. THP1 cells were pelleted and 702 resuspended in lentiviral supernatant containing polybrene. The next day, cells were 703 pelleted and resuspended in fresh growth medium. After overnight incubation, cells 704
were once again pelleted and resuspended in growth medium containing 10µg/ml 705 blasticidin or 1µg/ml puromycin (both Gibco) depending on which vector was used. 706
Surviving cells were used for experiments. 707 708 cGAMP-loaded VLPs 709 710
Empty VLPs or VLPs which incorporated cGAMP were generated using a modified 711 procedure based on a previously described method (Bridgeman et al., 2015) . 1.4x10 6 712
HEK293T cells were seeded per well in 6-well plates. The next day, cells were 713 transfected with 2µg of plasmids pDEST31/FLAG-ORF9 or pDEST31/FLAG-GFP, 1µg 714 pGag-eGFP (NIH AIDS reagent program), 500ng pVSV-G, and 1µg of 715 pcDNA3.2/hcGAS or pcDNA3.2/empty-vector. VLPs were harvested as described 716
above. At the end of VLP production, cells were lysed in RIPA buffer and analysed by 717
immunoblotting. 718
1.75x10 5 HEK293 cells were seeded per well in 24-well plates. The next day, cells were 719 overlaid with VLP solutions neat or 1:2 diluted in DMEM in the presence of 8µg/ml 720 polybrene (Sigma Aldrich) in duplicate. 16 hours later, supernatants were used for IFN 721 bioassay (see below). The cells were resuspended in PBS and stained with 1µg/ml 722 DAPI (Sigma Aldrich) in PBS for 10min. Cells were washed, fixed with BD CellFix (BD) 723
and analysed immediately on Attune NxT Acoustic Focusing Cytometer (Thermo 724 Fisher). Cells were gated on single, live events. A GFP + gate was set based on 725 uninfected cells. 726 727 IFN Bioassay 728 729
Type I IFN in cell culture supernatants was measured using HEK293-ISRE-Firefly 730 luciferase reporter cells (clone 3C11) as described previously (Bridgeman et al., 2015) . 731 4x10 4 3C11 cells were seeded per well into 96-well plates in growth medium. The next 732 day, test supernatants were clarified by centrifugation and overlaid onto 3C11 cells 733 seeded before. A standard consisting of 2-fold dilutions of recombinant IFN-A/D 734 (Sigma-Aldrich) was analysed in parallel. After overnight incubation reporter activation 735
in 3C11 cells was assessed by measuring luciferase activity using ONE-Glo luciferase 736 assay (Promega). 737 738 THP1 Knockout Cell Generation 739 740
For generation of knockout cells using CRISPR/Cas9 technology the pX458-mRuby 741 plasmid encoding the Cas9 protein, the sgRNA, and mRuby was used (Hertzog et al., 742 2018). 1x10 7 THP1 cells were transiently transfected with 50µg of respective pX458 743 plasmids using Lipofectamine LTX (Invitrogen) and incubated overnight. The next day 744 cells were stained with 10µg/ml DAPI in PBS for 10min. After resuspension of cells in 745 growth medium, live, mRuby-positive cells were FACS-sorted into eppendorf tubes 746 containing growth medium with 20% FCS. The suspension of sorted cells was diluted 747
with special growth medium (50% conditioned THP1 medium, 40% fresh RPMI with 748 10% FCS, 10% additional FCS) to one or three cells per 200µl. 200µl cell suspension 749
were then dispensed into each well of a 96-well plate (one or three cells per well). The 750 cells were incubated for several weeks until clones grew out. 751
The absence of the targeted protein in each clone was assessed by immunoblot 752
analysis. For functional validation, 1.5x10 5 cells were seeded per well into 96-well 753 plates in growth medium containing 10ng/ml PMA (Sigma-Aldrich). The next day cells 754
were transfected with 5ng IVT-RNA (Rehwinkel et al., 2010) 6.125x10 6 THP1 cells were seeded per well in 6-well plates in growth medium 778
containing 10 ng/ml PMA (Sigma-Aldrich). As a control, 1.625x10 6 MeWo cells were 779 seeded in MEM. The next day cells were washed with PBS and overlaid with PBS 780
containing CellTrace Far Red dye (Invitrogen) diluted 1:5,000. Cells were labelled for 781 15min at 37°C, an excess of growth medium was added and cells were incubated for 782 another 5min. Meanwhile, aliquots of uninfected and VZV-infected MeWo cells were 783 thawed, washed, and resuspended in MEM. Cells were counted and their 784
concentration was adjusted to 6.25x10 5 live cells per ml (for THP1 cells) or 1.25x10 5 785 live cells per ml (for MeWo cells) with MEM. Medium was removed from labelled cells 786
and cells were overlaid with 2ml MeWo -/+VZV cell suspension. Cells were incubated 787 at 37°C for 1 hour. The cell suspension was removed, adherent cells were washed 788 with PBS, overlaid with their respective growth medium and incubated for 48 hours. 789
Supernatants were removed from cells, clarified by centrifugation and stored at -80°C. 790
CXCL10 levels were determined using Human CXCL10/IP-10 Quantikine ELISA Kit 791 (R&D Systems) according to manufacturer's instructions. Cells were washed with PBS 792
and incubated with Trypsin-EDTA until they started to detach. Growth medium was 793 added, cells were resuspended by gentle pipetting and transferred to FACS tubes on 794
ice. 45% of cell suspension were transferred to eppendorf tubes on ice for extraction 795 of RNA and generation of protein lysates, respectively. The cells in those eppendorf 796 tubes were pelleted, washed with PBS, and then lysed either in RLT buffer and 797 processed for RT-qPCR or lysed in RIPA buffer and processed for immunoblot 798 analysis. Remaining cells in FACS tubes were used for analysis by flow cytometry. 799 800
Pulldowns 801 802
1.4x10 7 HEK293T cells were seeded in 15cm cell culture dishes. an aliquot was stored as unbound fraction from each sample, and beads were washed 811 three times in lysis buffer. Input, unbound, and bound fractions were subjected to 812
immunoblotting. For pulldowns from stably transduced THP1 cells, cells were seeded 813 at 2x10 7 per dish in 15cm cell-culture dishes in growth medium containing 10ng/ml 814 PMA. Lysates were generated the next day and processed as described above. For 815 pulldowns of recombinant proteins, 3µl recombinant cGAS-HA protein was mixed with 816
1.5µl FLAG-ORF9 or FLAG-GFP in IP buffer. IP was performed as described above.
817
For pulldowns from VZV-infected cells, 2.2x10 7 THP1 cells and 4x10 6 HaCaT cells 818
were seeded in 10cm dishes (in the presence of 10ng/ml PMA for THP1 cells). The 819
next day cells were overlaid with 1.25x10 7 MeWo cells infected with VZV or VZV ORF9-820 V5 for 1 hour and afterwards washed with PBS. Lysates were generated 48 hours later 821
as described above. 822 823
Far western 824 825
The experimental procedure for far western was based on a protocol previously 826
described ( inoculated using the starter culture. OD600 was measured in intervals and, for VZV 867 ORF9 and GFP, recombinant protein expression was induced by adding 0.1mM IPTG 868
once OD reached 0.6. Bacteria were grown 3 hours at 37°C. For expression of 869 recombinant cGAS and cGAS-HA, bacteria were grown to OD 0.8 and chilled to 18°C. 870
Protein expression was induced by adding 0.4mM IPTG and bacteria were incubated 871
for 16 hours at 18°C. For all proteins, bacteria were pelleted at 6,000g for 7min and 872
the pellet was resuspended in 12ml lysis buffer (20mM TRIS pH7.4, 500mM NaCl, 873 0.5mM EDTA, 0.5mM EGTA, 0.5% NP40, 1:100 Protease Inhibitor Cocktail 874 (CellSignaling Technology)). The suspension was sonicated on ice three times at 20% 875 amplitude with 15 sec ON and 30 sec OFF (Branson Sonifier). Insoluble material was 876 removed by centrifugation for 15min at 24,000g. In the meantime, 150µl Glutathione 877
Sepharose beads (GE Healthcare) were prepared according to manufacturer's 878
instructions. The beads were added to the clarified lysate and incubated under rotation 879
for 4 hours at 4°C. The beads were pelleted by centrifugation at 500g and washed five 880
times with lysis buffer. The beads were washed once in PreScission Cleavage buffer 881 (50mM TRIS pH 7.5, 150mM, 1mM freshly added DTT) and resuspended in 500µl 882
PreScission Cleavage buffer. After addition of 12µl PreScission Protease (GE 883
Healthcare), the suspension was incubated under rotation for 3 hours at 4°C. The 884 supernatant containing the recombinant protein was separated from beads and stored 885 at -80°C. Aliquots from the various purification steps were analysed by SDS-PAGE 886
and subsequent staining of the gel with EZBlue Gel Staining Reagent (Sigma Aldrich). 887
Based on band intensities the protein concentrations were estimated to be ca. 1µg/µl 888 for FLAG-ORF9 and FLAG-GFP, and ca. 0.5µg/µl for cGAS and cGAS-HA. 889 890
Immunoblotting 891 892
Protein concentrations in lysates were determined using Pierce BCA Protein Assay Kit 893 (Thermo Scientific) and equalised by dilution of samples with lysis buffer. 894
Subsequently, 4x NuPAGE LDS Sample Buffer (Invitrogen) was added and samples 895
were incubated at 95°C for 10min. Samples were run on NuPAGE Novex 4-12% Bis-896 TRIS gels (Invitrogen) using NuPage MOPS-SDS running buffer (Invitrogen). Proteins 897
were subsequently blotted onto PROTRAN Pure nitrocellulose membrane 898 (PerkinElmer) using transfer buffer (25mM TRIS, 192mM glycine). Membranes were 899 blocked with 5% skim milk powder (Sigma-Aldrich) in TBS containing 0.1% Tween-20 900
(5% milk TBS-T) for 1 hour at room temperature and were then incubated with primary 901 antibodies in 5% milk TBS-T overnight at 4°C. Primary antibodies that bind to 902 phosphorylated residues were diluted in 5% BSA in TBS-T. Membranes were washed 903 thrice with TBS-T and incubated with HRP-coupled secondary antibodies in 5% milk 904 TBS-T for 1 hour at room temperature. After three further washes with TBS-T, proteins 905
were detected using Western Lightning Plus-ECL (PerkinElmer) and the iBright 906 FL1000 Imaging System (Thermo Fisher) or Amersham Hyperfilm MP (GE 907
Healthcare). If needed, antibodies were stripped from the membrane with stripping 908 buffer (200mM glycine, 0.1% SDS, 1% Tween-20, pH 2.2) for 20min at room 909 temperature. Membranes were washed with TBS-T, blocked as described above and 910 re-probed. 911 912
RT-qPCR 913 914
Cells were lysed in RLT Plus buffer and RNA was extracted using RNeasy Plus Mini 915
Kit (Qiagen). The RNA was reverse transcribed using SuperScript IV Reverse 916
Transcriptase (Invitrogen) and oligo-dT primers (Invitrogen). The qPCR reaction 917
containing TaqMan Universal PCR Master Mix (Applied Biosystems) and TaqMan 918
Primer/Probes was run on QuantStudio 7 Flex Real-Time PCR System (Thermo 919
Fisher) with standard settings. Gene expression was analysed with the Ct method 920
using GAPDH expression for normalisation. Taqman primer/probes used were: 921 GAPDH (Hs02758991_g1), IFNB1 (Hs02621180_s1), IFI44 (Hs00951349_m1), and 922 IFNL1 (Hs00601677_g1). 923 924
Protein sequence analysis 925 926
The HSV-1 VP22 (PDB: 4XAL) and MHV68 ORF52 (PDB: 2OA5) crystal structures 927 were used to graphically represent secondary structure features. For VZV ORF9 928
(UniProt accession Q4JQW6) and KSHV ORF52 (UniProt accession F5HBL8), 929 structural features and sequence disorder was predicted by the PROFphd secondary 930 structure prediction algorithm through submission of protein sequences to the 931 predictprotein.org web interface (Yachdav et al., 2014 
